Video
Next-generation imaging and node-positive prostate cancer
Author(s):
Video Player is loading.
Jason Zhu, MD, a medical oncologist at Levine Cancer Institute, part of Atrium Health, discusses how next-generation imaging, such as PSMA-PET imaging, is critical to advancing personalized medicine in patients with lymph node–positive prostate cancer after prostatectomy.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Kelly Stratton, MD, reacts to FDA approval of Gozellix for prostate cancer imaging
PSMA PET and treatment intensification in mHSPC
Amar Kishan, MD, highlights ongoing research on reducing toxicity in SBRT
Amar Kishan, MD, on implications of MIRAGE trial data
Amar Kishan, MD, shares 2-year data on MRI-guided vs CT-guided SBRT
Amar Kishan, MD, outlines the rationale for the MIRAGE trial
Michael Cookson, MD, on potential future applications of PSMA-PET
Jeremie Calais, MD, highlights key elements of PSMA-PET reporting template
Michael Cookson, MD, on challenges with PSMA-PET imaging
Jeremie Calais, MD, on development of a prostate cancer imaging reporting template
Related Content
